This condition is classified as a demyelinating disease, meaning the protective myelin sheath around nerve fibers gradually deteriorates. As myelin breaks down, communication between the brain and muscles becomes increasingly impaired, resulting in progressive loss of coordination, strength, and motor control.
Disease Mechanism
LEMP-2 is caused by a specific genetic mutation that affects the normal structure and function of white matter pathways. Over time, damage to the myelin sheath leads to slowed or blocked nerve signal transmission, particularly in the spinal cord and brainstem regions that control movement and balance.
Because the disease targets the central nervous system, both upper and lower motor function can be affected, leading to a combination of weakness, ataxia, and coordination problems.
Clinical Signs
Clinical signs of LEMP-2 usually appear in young to adult dogs, depending on the severity of the mutation. Early symptoms may be subtle and gradually worsen over time. Common signs include:
- Hind limb weakness or stiffness
- Unsteady or wobbly gait (ataxia)
- Difficulty rising or climbing stairs
- Loss of coordination and balance
- Muscle tremors or stiffness
- Reduced exercise tolerance
- Progressive difficulty walking
As the disease progresses, affected dogs may experience worsening mobility, eventually leading to severe difficulty standing or walking without assistance. In advanced stages, both hind and forelimbs may be involved.
Importantly, cognitive function is often less affected than motor function, meaning dogs remain alert and responsive even as physical abilities decline.
Diagnosis
Diagnosis of LEMP-2 involves a combination of neurological examination, imaging, and genetic testing.
Veterinary neurologists may use:
- MRI (Magnetic Resonance Imaging) to identify white matter abnormalities
- Neurological reflex testing to assess motor function
- In some cases, cerebrospinal fluid (CSF) analysis
However, the most definitive and early diagnostic tool is DNA testing, which identifies the mutation responsible for LEMP-2 before clinical signs appear.
Genetic Testing (LEMP-2 Test)
The LEMP-2 genetic test is performed using a cheek swab or blood sample. The DNA is analyzed to determine the dog’s genetic status.
Results are generally reported as:
- Clear (Normal): No mutation detected; no increased risk of LEMP-2
- Carrier: One copy of the mutation; typically no clinical signs but can pass the gene to offspring
- Affected: Two copies of the mutation; high risk of developing progressive neurological disease
Management and Care
There is currently no cure for LEMP-2, and the condition is progressive. Management focuses on supportive care to maintain mobility and quality of life:
- Physiotherapy and controlled exercise
- Mobility assistance devices (harnesses, carts)
- Home modifications to prevent injury
- Pain and muscle spasm management if needed
- Regular neurological monitoring
As the disease progresses, supportive care becomes increasingly important for maintaining comfort.
Importance in Breeding
LEMP-2 is a significant concern in breeding programs because it is inherited. Genetic testing allows breeders to identify carriers and avoid high-risk matings, helping reduce the prevalence of this debilitating neurological condition in future generations.
Summary
The Leukoencephalomyelopathy (LEMP-2) Health Test is an essential genetic screening tool that enables early detection of inherited white matter disease, supports responsible breeding decisions, and helps manage long-term neurological health and mobility in dogs.
